Recently, a dose-escalating phase I study protocol (3 + 3 design) was published for the treatment of radiation-induced xerostomia in patients with head and neck cancer with interferon-gamma-stimulated autologous bone marrow stromal cells.41 The results of this study are not yet available. The gene discussed is IFNG; the disease is xerostomia.